Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma CDMO offers integrated end-to-end solutions for development & commercialization of intermediates & APIs for small molecules.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    veranova-m-2025-06-30

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-06-30

    Virtual Booth

    An Enquiry

    Menu

    Pirepemat

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IRLAB Reports Phase IIb Results of Pirepemat in Parkinson
    IRLAB Reports Phase IIb Results of Pirepemat in Parkinson

    05 Mar 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/irlab-reports-topline-results-from-a-phase-iib-study-of-pirepemat-in-p-995983

    ACCESSWIRE
    05 Mar 2025
    Share Share
    IRLAB Granted Patent For Pirepemat Expanding Patent Protection In The US
    IRLAB Granted Patent For Pirepemat Expanding Patent Protection In The US

    18 Sep 2024

    // ACCESSWIRE

    https://www.accesswire.com/919554/irlab-granted-additional-patent-for-its-drug-candidate-pirepemat-expanding-the-patent-protection-in-the-us

    ACCESSWIRE
    18 Sep 2024
    Share Share
    IRLAB's Phase IIb Study Of Pirepemat Proceeds After Positive Safety Review
    IRLAB's Phase IIb Study Of Pirepemat Proceeds After Positive Safety Review

    02 Jul 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=884181&lang=en

    ACCESSWIRE
    02 Jul 2024
    Share Share
    IRLAB’s Phase IIb Study with Pirepemat - React-PD - Provides New Insights
    IRLAB’s Phase IIb Study with Pirepemat - React-PD - Provides New Insights

    06 Feb 2024

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=831422&lang=en

    ACCESSWIRE
    06 Feb 2024
    Share Share
    IRLAB is Granted Additional Patent for Drug Candidate Pirepemat
    IRLAB is Granted Additional Patent for Drug Candidate Pirepemat

    12 Dec 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=815915&lang=en

    ACCESSWIRE
    12 Dec 2023
    Share Share